- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape
Key opinion leaders provide a concise overview of the atopic dermatitis (AD) treatment landscape, focusing on the role of topical therapy, and highlight the current unmet needs in AD management.
EP: 1.Tackling Key Concerns in Atopic Dermatitis + Biologic Use
EP: 2.Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape
EP: 3.Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment
EP: 4.Experts Discuss Long-Term Effects and Monitoring in AD Therapy
EP: 5.Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD
EP: 6.The Patient Journey: Effectively Managing AD Itch Early On
EP: 7.Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies
EP: 8.Experts Share Final Insights to Optimize Atopic Dermatitis Patient Care
- Provide a brief overview of the treatment landscape, and where topical therapies and systemic therapies fit into this landscape. What are the current unmet needs from your perspective?
- Please incorporate a discussion of the following topical therapies:
- Corticosteroids
- Crisaborole – AD-301/AD-302, CrisADe CARE 1
- Ruxolitinib – TRuE-AD1/TRuE-AD2 – original publication, long-term follow up
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
